TMPRSS2 and metastatic neoplasm: For rearrangements of TMPRSS2 and/or ERG, previous findings showed ERG rearrangements in 30–50% of localized prostate cancers [1], [2], [4], [5], [22] and 40–50% of metastatic diseases [4], [23]–[25].